Starling Oncology opened lower at $4.10, compared with its previous close of $4.20. In the last trading session, the stock traded between $3.67 and $4.24. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Starling Oncology is now worth
$ 38.23
Resulting in a loss of
$ 61.77 (61.77%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.47 (-11.07%)
Day High
$4.24
Day Low
$3.67
Day Open
$4.10
Prev Close
$4.20
Volume
60,29,183
1W Return
-46.09%
1M Return
-45.99%
3M Return
-39.69%
6M Return
-6.86%
1Y Return
11.16%
Fundamentals
Market Cap ($ Mn)
381
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-48.33%
EPS (TTM)
$-0.13
Investment Returns
1 Week
-46.09%
1 Month
-45.99%
3 Months
-39.69%
6 Months
-6.86%
9 Months
42.56%
Financials
Quarterly
All values in $ Mn
119.8
Jun 25
136.6
Sep 25
142.0
Dec 25
147.4
Mar 26
161.3
Jun 26
169.8
Sep 26
Updates
6Nov
B. Riley reiterates Buy on Starling Oncology, cuts target to $10
B. Riley Securities maintained a Buy rating on Starling Oncology. Price target lowered from $11 to $10 by analyst Yuan Zhi. Rating reiterated despite the reduction in price target.
6 days ago
6Nov
Starling Oncology narrows FY26 revenue guidance to $650M-$660M
Starling Oncology narrowed FY26 revenue guidance to $650 million-$660 million. New guidance upper limit is $10 million lower than the previous $670 million cap. Revised outlook is below the analyst consensus estimate of $663.7 million. Q3FY26 revenue rose 24% YoY to $169.8 million with positive adjusted EBITDA.
7 days ago
7Aug
Oncology Institute raises FY26 sales guidance to $650M-$670M
Oncology Institute raised its FY2026 sales guidance from $630.000M-$650.000M to $650.000M-$670.000M. This revision beats the market estimate of $651.941M, indicating strong operational confidence and potential revenue upside for shareholders.
3mo ago
7Aug
The Oncology Institute Q2 Results: Sales rise 34.62% YoY
The Oncology Institute posted Q2 sales of $161.282 million, up 34.62% YoY and beating estimates by 3.92%. However, EPS of $(0.08) missed the $(0.06) estimate by 33.33%, with losses widening 46.67% from last year's $(0.15).
3mo ago
10Jul
BTIG maintains Buy on Oncology Institute, raises target to $9
BTIG analyst David Larsen maintained a Buy rating for Oncology Institute and raised the price target from $8 to $9, highlighting confidence in the company's performance. This follows a previous initiation by Lake Street analyst Ben Haynor with a Buy rating and a $10 price target.
4mo ago
17Jun
Needham raises Oncology Institute price target to $7
Needham analyst Matthew Shea maintains a Buy rating on Oncology Institute (NASDAQ: TOI) and raises the price target from $5 to $7, signaling continued confidence in the company's stock.
